At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

The financing will in part support development of the firm's PI3K inhibitor paxalisib in PIK3CA-mutated brain cancer and HER2-positive breast cancer.

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

This month, the firm also performed a 1-for-15 reverse share split to maintain compliance with Nasdaq listing requirements.

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

Despite regulatory setbacks, the petitioners believe that survival and other data they've collected themselves are worth ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...

Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Blood Cancer UK is launching early career grants following a tough pandemic-era funding climate, while US funders worry about ...